ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > US 50,000,000 Prospectus

<< Previous

Bullboard Posts

Next >>

Comment by Mole101on Jul 08, 2021 3:12pm

141 Views

Post# 33515793

RE:US 50,000,000 Prospectus

Question :
Can a company like Biogen, Sanofy ... be able to participate on the private placement as a way to invest and taking a percentage on PMN? If I remember correctly , Biogen and Amorfix/PMN worried together back in the 2012/13?

farmerjane wrote: What's the plan here? With a market cap of cdn 73,000,000 keep the information suppressed then issue to a select Boston group and management (all in the familiy) shares at this price equalling the current market cap? Management but not Cashman participating? Have you noticed there press releases lately, sub-standard out of date internet, no social media.

<< Previous

Bullboard Posts

Next >>

NervGen Pharma: Proof that NVG-291 works?